Literature DB >> 23550525

Strategies for early detection of chronic Q-fever: a systematic review.

Cornelia C H Wielders1, Gabriëlla Morroy, Peter C Wever, Roel A Coutinho, Peter M Schneeberger, Wim van der Hoek.   

Abstract

BACKGROUND: Chronic Q-fever, a condition with high morbidity and mortality, may develop after an acute infection with Coxiella burnetii (acute Q-fever). Several strategies have been suggested for early detection of chronic Q-fever, focusing on follow-up of known acute Q-fever patients and detection of asymptomatic or unknown chronic infections. As there is no international standard or consensus, the aims of this study were to summarise the available literature and assess the evidence for different follow-up and screening strategies.
DESIGN: We conducted a systematic review by searching PubMed and Embase. Twenty articles were included, of which fourteen only provided information on follow-up of known acute Q-fever cases, four presented data on identification of previously unknown C. burnetii infections, and two had information on both topics.
RESULTS: The conversion rate of acute to chronic Q-fever ranged from 0 to 5.0%. Most studies advised serological follow-up of acute Q-fever patients, but without consistent advice on optimum timing and duration. The recommendation to use echocardiography for all acute Q-fever patients to detect valvular damage remains controversial. Screening of high-risk patients in an outbreak setting is advised by studies investigating such strategy.
CONCLUSIONS: There is sufficient evidence to support serological follow-up of all known acute Q-fever patients at least once during the first year following the acute infection, and more frequently in patients with known risk factors for chronic disease, such as heart valve- or vascular prosthesis. Screening of risk groups should be considered in outbreaks of Q-fever.
© 2013 Stichting European Society for Clinical Investigation Journal Foundation. Published by John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2013        PMID: 23550525     DOI: 10.1111/eci.12073

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  10 in total

1.  Comparison of Different Commercially Available Enzyme-Linked Immunosorbent Assays with Immunofluorescence Test for Detection of Phase II IgG and IgM Antibodies to Coxiella burnetii.

Authors:  Larissa Dangel; Daniela Koempf; Silke F Fischer
Journal:  J Clin Microbiol       Date:  2020-01-28       Impact factor: 5.948

2.  Serological follow-up in patients with aorto-iliac disease and evidence of Q fever infection.

Authors:  J C J P Hagenaars; N H M Renders; A S van Petersen; S O A Shamelian; M G L de Jager-Leclercq; F L Moll; P C Wever; O H J Koning
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-03-12       Impact factor: 3.267

3.  Long-Term Serological Follow-Up of Acute Q-Fever Patients after a Large Epidemic.

Authors:  Cornelia C H Wielders; Joris A F van Loenhout; Gabriëlla Morroy; Ariene Rietveld; Daan W Notermans; Peter C Wever; Nicole H M Renders; Alexander C A P Leenders; Wim van der Hoek; Peter M Schneeberger
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

4.  Should Acute Q-Fever Patients be Screened for Valvulopathy to Prevent Endocarditis?

Authors:  Marit M A de Lange; Laura E V Gijsen; Cornelia C H Wielders; Wim van der Hoek; Arko Scheepmaker; Peter M Schneeberger
Journal:  Clin Infect Dis       Date:  2018-07-18       Impact factor: 9.079

5.  Population Screening for Chronic Q-Fever Seven Years after a Major Outbreak.

Authors:  Gabriëlla Morroy; Wim van der Hoek; Jelle Albers; Roel A Coutinho; Chantal P Bleeker-Rovers; Peter M Schneeberger
Journal:  PLoS One       Date:  2015-07-01       Impact factor: 3.240

6.  Characteristics of hospitalized acute Q fever patients during a large epidemic, The Netherlands.

Authors:  Cornelia C H Wielders; Annemarie M H Wuister; Veerle L de Visser; Monique G de Jager-Leclercq; Cornelis A R Groot; Frederika Dijkstra; Arianne B van Gageldonk-Lafeber; Jeroen P G van Leuken; Peter C Wever; Wim van der Hoek; Peter M Schneeberger
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

7.  Risk of chronic Q fever in patients with cardiac valvulopathy, seven years after a large epidemic in the Netherlands.

Authors:  Marit M A de Lange; Arko Scheepmaker; Wim van der Hoek; Monique Leclercq; Peter M Schneeberger
Journal:  PLoS One       Date:  2019-08-22       Impact factor: 3.240

8.  Acute Q Fever in an Ankylosing Spondyloarthritis Patient Treated with Etanercept.

Authors:  A Guiga; D Khalifa; W Ben Yahia; N El Amri; A Atig; N Ghannouchi
Journal:  Case Rep Rheumatol       Date:  2021-06-01

9.  Q Fever Risk in Patients Treated with Chronic Antitumor Necrosis Factor-Alpha Therapy.

Authors:  Julianna Hirsch; Anna Astrahan; Majed Odeh; Nizar Elias; Itzhak Rosner; Doron Rimar; Lisa Kaly; Michael Rozenbaum; Nina Boulman; Gleb Slobodin
Journal:  Case Rep Infect Dis       Date:  2016-08-30

Review 10.  Q fever in Spain: Description of a new series, and systematic review.

Authors:  Vanesa Alende-Castro; Cristina Macía-Rodríguez; Ignacio Novo-Veleiro; Xana García-Fernández; Mercedes Treviño-Castellano; Sergio Rodríguez-Fernández; Arturo González-Quintela
Journal:  PLoS Negl Trop Dis       Date:  2018-03-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.